Related Tags >> FDA Type 2 Diabetes biotechnology company Merck Serono

release formulation News

Most Popular release formulation Story

Press Release: Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S.

January 24, 2007 — 1:04pm ET | By Maureen Martino

Press Release: Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S.

Read more...

release formulation Press Releases

Ultragenyx Granted Orphan Drug Designation for UX001 SA-ER for the Treatment of Hereditary Inclusion Body Myopathy (HIBM)
Ultragenyx Initiates Phase 1 Clinical Study of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Muscle Wasting Disease
Flamel Technologies Announces Increase in Cash Position; Second Quarter 2011 Results
Lipid Therapeutics Announces Positive Topline Phase IIb Results With LT-02 in Patients With Ulcerative Colitis
VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®

Latest Headlines

ALSO NOTED: Ambrilia touts data; Amarin raises $60M; and much more...
May 14, 2008
Orexigen claims success in weight-loss trial
July 24, 2007
Press Release: Depomed Reaquires Rights to ProQuin XR
July 5, 2007
Press Release: Astellas Receives an Action Letter from FDA for NDA of FK506 MR in the U.S.
January 24, 2007
Press Release: Elbion Acquires Late-Stage Product Candidate For Treatment Of Alcohol Dependence
January 19, 2007
Press Release: Ambrilia Biopharma Announces European Licensing Partnership With TEVA
November 14, 2006
Critical Therapeutics slashes staff in restructuring
October 26, 2006
Tramadol-ER fails in latest Phase III trial
September 10, 2006
ALSO NOTED: Ono to start cancer trials; Ligand CEO steps down; and much more...
July 31, 2006
ALSO NOTED: Celera moves to cut staff; FDA expands Emend use; FDA approves Perrigo gel; and much more...
January 10, 2006
VC: Biolex leads with $36M in round 2
September 7, 2005
Biolex garners $36M in second round
August 31, 2005

Paid Research Reports

More Research Reports >>